Targeted microwave ablation of localised prostate cancer ( <scp>VIOLETTE trial</scp> ): a prospective multicentre study
Targeted microwave ablation using OBT Fusion technology appears to be a safe and effective focal therapy procedure for localised intermediate-risk PCa. The VIOLETTE trial achieved its primary endpoint, with 81% patients free of in-field csPCa at 12 months.
Authors
- Grégoire Robert
- Franck Bladou (ORCID: https://orcid.org/0000-0001-6825-4400)
- A. Messas
- Thierry Piechaud
- Romain Diamand
- Nicolas Barry Delongchamps
- Roland van Velthoven
- Jean‐Louis Hoepffner
- Julien Anract
- Jean‐Baptiste Roche
- Alexandre Peltier
- Eric Potiron
Institutions
- Hôpital américain de paris (FR)
- Université Libre de Bruxelles (BE)
- Université de Bordeaux (FR)
- Université Paris Cité (FR)
- Institut Jules Bordet (BE)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Hôpital Cochin (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Institut Génétique Nantes Atlantique (FR)
- Saint Augustine's University (US)
Publication Details
- Journal
- British Journal of Urology
- Published
- 2026-03-11
- DOI
- https://doi.org/10.1111/bju.70220
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00